We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Blood Test Identifies Prediabetics with Highest Risk of Developing Diabetes Before Symptoms Develop

By LabMedica International staff writers
Posted on 27 Feb 2023
Print article
Image: The GlycoMark test is a 10 minute, two-step enzymatic kinetic assay (Photo courtesy of Precision Diabetes)
Image: The GlycoMark test is a 10 minute, two-step enzymatic kinetic assay (Photo courtesy of Precision Diabetes)

Type 2 diabetes takes years to develop but is preventable if caught early. However, just 50% of people with prediabetes go on to develop full-blown diabetes over a period of 10 years. Unfortunately, current diabetes tests such as hemoglobin A1C and fasting glucose are incapable of accurately identifying prediabetic individuals who are at the highest risk of progression. Now, a blood test can identify high-risk, asymptomatic patients with prediabetes who cannot be detected by standard diabetes tests, hemoglobin A1C and glucose. The blood test meets a critical clinical need as it can be used by physicians to identify patients closest to developing type 2 diabetes and provide treatment to prevent the onset of the disease.

GlycoMark from Precision Diabetes, Inc. (Raleigh, NC, USA) is an FDA-cleared, non-fasting serum or plasma test for monitoring blood glucose variability in people with diabetes. The GlycoMark test provides quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. As the GlycoMark test reflects a progressive decline of functional beta-cell mass, it can identify prediabetic patients with the highest risk of developing diabetes before the first symptoms develop. Most high-risk patients can prevent the development of type 2 diabetes by making lifestyle changes such as eating a well-balanced diet, exercising and maintaining a healthy body weight.

In a new study, the GlycoMark blood test has shown that it can identify high-risk, asymptomatic patients with prediabetes, not detected by standard diabetes tests, hemoglobin A1C and glucose. The finding is extremely important as there is a significant clinical need for a sensitive and robust biomarker of functional beta-cell mass (beta cells are cells in the pancreas that produce insulin). A functional beta-cell mass biomarker is essential to identify which prediabetic individuals have the highest risk of progression to diabetes.

"This study not only has significant clinical implications as there has been a long search for an accurate biomarker of beta-cell function, but given the sheer numbers of people with prediabetes, it is important to target the highest-risk patients from a public health and economic standpoint," said Eric Button, CEO of Precision Diabetes, Inc. "GlycoMark will be an important tool in stratifying these patients for follow-up treatment."

Related Links:
Precision Diabetes, Inc. 

Unit-Dose Twist-Tip BFS
Gold Supplier
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
New
Gold Supplier
Diagnostic Reader
Acucy System
New
IFA Automation Solution
dIFine 30 System

Print article

Channels

Molecular Diagnostics

view channel
Image: Medication, sepsis and inadequate blood supply to the kidneys are potential causes of AKI (Photo courtesy of Freepik)

Blood- And Urine-Based Biomarker Tests Could Identify Treatment of Acute Kidney Injury

Hospitalized patients who experience an acute kidney injury (AKI) often face unfavorable outcomes post-discharge, with limited effective treatment options. AKI can stem from various causes, such as sepsis,... Read more

Hematology

view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more

Immunology

view channel
Image: The first ever diagnostic test accurately predicts patient response to immunotherapy (Photo courtesy of Cofactor)

Immunotherapy Predictive Test Could Spare Cancer Patients from Unnecessary Chemotherapy

In recent years, there has been a significant increase in clinical trials for new cancer drugs. However, only a select group of patients have found success with these newer immunotherapies, which utilize... Read more

Microbiology

view channel
Image: New method reveals bacterial reaction to antibiotics within minutes (Photo courtesy of Freepik)

New Method to Reveal Bacterial Reaction to Antibiotics in Five Minutes Could Help Create Rapid Molecular Test

Severely sick patients suffering from bacterial infections often require immediate treatment to prevent serious health complications, making it vital for physicians to quickly identify the appropriate antibiotic.... Read more

Pathology

view channel
Image: navify digital solutions can helping labs mitigate unique quality challenges (Photo courtesy of Roche)

Cloud-Based Digital Solution Allows Labs to Track Test Samples along Entire Diagnostic Journey

Diagnosing a disease involves a meticulous procedure of monitoring a patient's diagnostic sample throughout its entire journey, which aids in clinical decision-making. However, there aren't any standardized... Read more

Technology

view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more

Industry

view channel
Image: The global hemostasis diagnostics market is expected to reach USD 3.95 billion by 2025 (Photo courtesy of Freepik)

Global Hemostasis Diagnostics Market Driven by Increase in Invasive Surgical Procedures

Injury or surgery naturally creates bleeding in living beings, which must be stopped to prevent excessive blood loss. The human body implements a protective mechanism known as hemostasis to stop excessive bleeding.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.